To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 January 2018 to Question 122358 on Orkambi: Republic of Ireland, whether he has had further discussions with his Irish counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
Lumacaftor/ivacaftor: Republic of Ireland